Beaufort Securities reaffirmed their speculative buy rating on shares of Tiziana Life Sciences PLC (LON:ADI) in a research note published on Wednesday.

ILLEGAL ACTIVITY WARNING: “Tiziana Life Sciences PLC (ADI) Receives “Speculative Buy” Rating from Beaufort Securities” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.thecerbatgem.com/2017/08/17/tiziana-life-sciences-plc-adi-receives-speculative-buy-rating-from-beaufort-securities.html.

About Tiziana Life Sciences PLC

Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. Its products in clinical stage include Milciclib and Foralumab. Its products in pre-clinical stage include TZLS-101 and TZLS-214.

Receive News & Stock Ratings for Tiziana Life Sciences PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences PLC and related stocks with our FREE daily email newsletter.